A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Loss of muscle and bone mass with age are significant contributors to falls and fractures among the elderly. Myostatin deficiency is associated with increased muscle mass in mice, dogs, cows, sheep and humans, and mice lacking myostatin have been observed to show increased bone density in the limb, spine, and jaw. Transgenic overexpression of myostatin propeptide, which binds to and inhibits the active myostatin ligand, also increases muscle mass and bone density in mice. We therefore sought to test the hypothesis that in vivo inhibition of myostatin using an injectable myostatin propeptide (GDF8 propeptide-Fc) would increase both muscle mass and bone density in aged (24 mo) mice. Male mice were injected weekly (20 mg/kg body weight) with recombinant myostatin propeptide-Fc (PRO) or vehicle (VEH; saline) for four weeks. There was no difference in body weight between the two groups at the end of the treatment period, but PRO treatment significantly increased mass of the tibialis anterior muscle (+ 7%) and increased muscle fiber diameter of the extensor digitorum longus (+ 16%) and soleus (+ 6%) muscles compared to VEH treatment. Bone volume relative to total volume (BV/TV) of the femur calculated by microCT did not differ significantly between PRO- and VEH-treated mice, and ultimate force (Fu), stiffness (S), toughness (U) measured from three-point bending tests also did not differ significantly between groups. Histomorphometric assays also revealed no differences in bone formation or resorption in response to PRO treatment. These data suggest that while developmental perturbation of myostatin signaling through either gene knockout or transgenic inhibition may alter both muscle and bone mass in mice, pharmacological inhibition of myostatin in aged mice has a more pronounced effect on skeletal muscle than on bone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional improvement of dystrophic muscle by myostatin blockade
Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S. (2002) · Nature · doi:10.1038/nature01154 · Cited by 831 · cited 2×
“These include utilization of myostatin-specific antibodies (Bogdanovich et al., 2002; LeBrasseur et al., 2009;Murphy et al., 2010;Wagner et al., 2008), a decoymyostatin receptor (ActRIIB-Fc; Bialek et al., 2008; Borgstein et al., 2009; Chiu et al., 2013; Lee et al., 2005), and myostatin propeptide…”
BackgroundThe roles of vitamin D in skeletal muscle: form, function, and metabolism
Girgis, C. M., Clifton-Bligh, R. J., Hamrick, M. W., Holick, M. F., & Gunton, J. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1012 · Cited by 567 · cited 1×
“Behavioral interventions such as resistance exercise or nutritional interventions such as vitamin D supplementation (Girgis et al., 2013) may improve muscle strength and/or neuromuscular control and proprioception, perhaps reducing fall risk.”
BackgroundRegulation of muscle growth by multiple ligands signaling through activin type II receptors
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505996102 · Cited by 501
Self-citationLeBrasseur, N. K., Schelhorn, T. M., Bernardo, B. L., Cosgrove, P. G., Loria, P. M., & Brown, T. A. (2009) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp068 · Cited by 180 · cited 7×
“Murphy et al. (2010), like LeBrasseur et al. (2009), used weekly doses of the PF-354 antibody but used a lower dose (10 mg/kg) for a longer treatment period— 14 weeks of treatment starting in mice aged 18 months.”
BackgroundMethodResultInfluentialHamrick, M. W., Ding, K.-H., Ponnala, S., Ferrari, S. L., & Isales, C. M. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080213 · Cited by 143
Self-citationIncreased Muscle Force Production and Bone Mineral Density in ActRIIB-Fc-Treated Mature Rodents
Chiu, C.-S., Peekhaus, N., Weber, H., Adamski, S., Murray, E. M., Zhang, H. Z., Zhao, J. Z., Ernst, R., Lineberger, J., Huang, L., et al. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt030 · Cited by 68 · cited 8×
“, 2010) and a decoy myostatin receptor (Chiu et al., 2013) can increase muscle mass in aged mice.”
BackgroundResultInfluential
Cited by
Muscle and bone, two interconnected tissues
Tagliaferri, C., Wittrant, Y., Davicco, M.-J., Walrand, S., & Coxam, V. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.03.002 · Cited by 390
Qin, Y., Peng, Y., Zhao, W., Pan, J., Ksiezak-Reding, H., Cardozo, C., Wu, Y., Divieti Pajevic, P., Bonewald, L. F., Bauman, W. A., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.770941 · Cited by 278
Intrinsic muscle clock is necessary for musculoskeletal health
Schroder, E. A., Harfmann, B. D., Zhang, X., Srikuea, R., England, J. H., Hodge, B. A., Wen, Y., Riley, L. A., Yu, Q., Christie, A., et al. (2015) · The Journal of Physiology · doi:10.1113/jp271436 · Cited by 145
Therapies for Musculoskeletal Disease: Can we Treat Two Birds with One Stone?
Girgis, C. M., Mokbel, N., & DiGirolamo, D. J. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0204-5 · Cited by 110
Inhibition of myostatin prevents microgravity-induced loss of skeletal muscle mass and strength
Smith, R. C., Cramer, M. S., Mitchell, P. J., Lucchesi, J., Ortega, A. M., Livingston, E. W., Ballard, D., Zhang, L., Hanson, J., Barton, K., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230818 · Cited by 48
Metadata
- Authors
- Arounleut, P., Bialek, P., Liang, L.-F., Upadhyay, S., Fulzele, S., Johnson, M., Elsalanty, M., Isales, C. M., & Hamrick, M. W.
- Venue
- Experimental Gerontology
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 48
- Issue
- 9
- Pages
- 898-904
- ISSN
- 0531-5565 (ISSN-L)
- OpenAlex
- W2036985965
- Cited by
- 66
- References
- 6
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength. https://app.cochat.ai/papers/10.1016/j.exger.2013.06.004
- The paper
- Arounleut, P., Bialek, P., Liang, L.-F., Upadhyay, S., Fulzele, S., Johnson, M., Elsalanty, M., Isales, C. M., & Hamrick, M. W. (2013). A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength. Experimental Gerontology. https://doi.org/10.1016/j.exger.2013.06.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.